CD36 is a co-receptor for hepatitis C virus E1 protein attachment

Area of Science:

• Virology
• Immunology
• Biochemistry

Background:

• Hepatitis C virus (HCV) infection remains a significant global health concern.
• Understanding viral entry mechanisms is crucial for developing effective antiviral therapies.
• Cluster of differentiation 36 (CD36) is implicated in lipid metabolism and cellular processes.

Purpose of the Study:

• To investigate the role of CD36 in HCV infection.
• To determine if CD36 acts as a co-receptor for HCV entry.
• To evaluate CD36 as a potential therapeutic target for HCV.

Main Methods:

• In vitro studies of HCV infection in cells with varying CD36 expression.
• Analysis of the interaction between CD36 and HCV E1 protein.
• Treatment with CD36 monoclonal antibodies and the inhibitor sulfo-N-succinimidyl oleate (SSO).
• Assessment of viral replication and entry inhibition.

Main Results:

• HCV infection increased both surface and soluble CD36 expression.
• CD36 directly interacts with HCV E1 protein, facilitating viral entry and replication.
• CD36's co-receptor function for HCV is distinct from SR-BI.
• CD36 inhibition by antibodies or SSO significantly reduced HCV replication.
• SSO demonstrated specific antiviral activity against HCV, with enhanced efficacy when combined with other anti-HCV drugs.
• SSO exhibited a favorable safety profile in mice.

Conclusions:

• CD36 acts as a specific co-receptor for HCV entry, interacting with the HCV E1 protein.
• Targeting CD36, particularly with inhibitors like SSO, represents a promising therapeutic strategy against HCV.
• CD36 inhibition offers a novel approach for HCV treatment, potentially overcoming resistance mechanisms.